Female breast cancer in Europe: statistics, diagnosis and treatment modalities

Flora Zagouri¹, Theodoros N. Sergentanis², Alexandra Tsigginou³, Constantine Dimitrakakis³, George C. Zografos⁴, Meletios-Athanassios Dimopoulos¹, Theodora Psaltopoulou²

¹Department of Clinical Therapeutics, Alexandra Hospital, ²Department of Hygiene, Epidemiology and Medical Statistics, ³Department of Obstetrics and Gynaecology, ⁴Propaedeutic Surgical Department, Hippocrateio Hospital, Medical School, University of Athens, Athens, Greece

Corresponding to: Flora Zagouri, MD, PhD. Department of Clinical Therapeutics, Alexandra Hospital, University of Athens, Greece; Vas Sofias Ave & Lourou str, Athens 11521, Greece. Email: florazagouri@yahoo.co.uk.

Submitted Jun 06, 2014. Accepted for publication Jun 09, 2014.
doi: 10.3978/j.issn.2072-1439.2014.06.18

View this article at: http://dx.doi.org/10.3978/j.issn.2072-1439.2014.06.18

In this issue of the Journal of thoracic diseases, Zeng et al. (1) present an extremely interesting synthesis of 145 population-based cancer registries submitting qualified cancer incidence and mortality data to National Cancer Registration Center of China. The authors provide interesting age-standardized incidence and mortality rates, highlighting higher incidence rates in urban areas as well as meaningful geographical disparities.

Based on the most recent data, China exhibits considerably lower incidence and mortality rates for female breast cancer than Europe; more specifically, the age-standardized rate (ASR) per 100,000 was equal to 25.9 in China (1), whereas the respective rates according to GLOBOCAN 2012 were 71.1 for Europe with Greece presenting with more favorable rates (43.9) (2) (Figure 1A). Regarding the lower rates in China, the underlying explanation remains elusive as a host of factors including genetic, environmental, lifestyle and somatometric differences have been acknowledged (3,4). As far as the favorable profile of Greece compared to the rest of Europe is concerned, once again the specific explanations remain to be uncovered; nevertheless, genetic differences, adherence to Mediterranean diet, consumption of olive oil, prolonged sun exposure (5-7) may have contributed.

In accordance with incidence rates, China exhibited lower breast cancer mortality rates [6.6 per 100,000 (1)], whereas the respective mortality rate in Europe was equal to 16.1 (2); of note, the discrepancies in mortality rates across Europe were relatively milder (Figure 1B). Especially

<table>
<thead>
<tr>
<th></th>
<th>Incidence (Age-standardized rate per 100,000)</th>
<th>Mortality (Age-standardized rate per 100,000)</th>
</tr>
</thead>
<tbody>
<tr>
<td>China (Zeng et al.)</td>
<td>25.9</td>
<td>6.6</td>
</tr>
<tr>
<td>Europe</td>
<td>71.1</td>
<td>16.1</td>
</tr>
<tr>
<td>Central-Eastern Europe</td>
<td>47.7</td>
<td>16.5</td>
</tr>
<tr>
<td>Northern Europe</td>
<td>89.4</td>
<td>16.3</td>
</tr>
<tr>
<td>Southern Europe</td>
<td>74.5</td>
<td>14.9</td>
</tr>
<tr>
<td>Western Europe</td>
<td>96</td>
<td>16.2</td>
</tr>
<tr>
<td>Greece</td>
<td>43.9</td>
<td>14.1</td>
</tr>
</tbody>
</table>

Figure 1 Incidence and mortality age-standardized rate in Europe, according to GLOBOCAN 2012.
regarding Greece, the bridging of the gap with the rest of Europe may be attributed to the lack of State implemented national screening program potentially leading to diagnosis at a more advanced stage, to the existence of geographically isolated, remote regions (small islands and mountainous regions) in the country, etc. Indeed, a recent study published by the Hellenic Cooperative Oncology Group pointed to worst outcomes from breast cancer among women residing in distant Greek regions (8). Nevertheless, these questions remain to be addressed by future studies as detailed relevant nationwide data are not currently available. Of note, previous studies issued by our research team in tertiary Breast Units have highlighted the suboptimal adherence of women to the worldwide breast cancer screening recommendations (9,10).

On the other hand, treatment modalities among Europe do not seem to exhibit significant differences given the common regulatory agency—European Medicines Agency (EMEA)—for the evaluation of approved agents, the adherence to European Society for Medical Oncology (ESMO) guidelines, etc. (11-13). However, national guidelines in each European country exist, exhibiting slight discrepancies in screening, treatment modalities and surveillance of female breast cancer patients.

In conclusion, it seems that the article by Zeng et al. (1) provides interesting insight into significant questions regarding female breast cancer epidemiology surpassing the boundaries of China. It seems important to develop careful public health plans, conduct screening strategies and adopt cancer prevention measures in order to guide scientific research applicable and treatment applicable to each country and consequently reduce breast cancer burden.

Acknowledgements

Disclosure: The authors declare no conflict of interest.

References


